Envista’s (NYSE:NVST) Q2 CY2026 Sales Beat Estimates
Envista Holdings (NYSE: NVST) reported Q2 CY2026 revenue of $730.5 million, up 7.1% year on year and about 2% above Wall Street estimates. Non-GAAP EPS was $0.41, up from $0.26 a year earlier, and 22.1% above consensus. Analysts expect next 12 months revenue growth of 1.1% and FY EPS around $1.47.
How this was made
The 30-second read
Why it matters
Q2 CY2026 results beat revenue and adjusted EPS expectations, and the article claims FY EPS guidance was raised, but it also highlights a slower expected revenue growth rate over the next 12 months.
Market read
Traders can reassess NVST’s near-term earnings power after a Q2 beat and guidance raise, while weighing the weaker forward revenue growth trajectory.
What to watch
The article notes a long-run adjusted operating margin decline over five years, so investors may focus on whether the recent margin improvement is durable.
Background
Envista Holdings is a global dental products company with brands including Nobel Biocare, Ormco, and DEXIS.
Ticker impact
Envista reported Q2 CY2026 revenue of $730.5M, up 7.1% YoY, beating Wall Street estimates by 2% and lifting adjusted EPS to $0.41.
Likely near-term positive drift, with upside capped by the projected 1.1% next-12-month revenue growth deceleration.
The article provides concrete Q2 results (revenue, EPS) and states FY EPS was raised above consensus, but also flags weaker forward revenue growth expectations.
Market effects
Dental products peers may see read-across interest if margin and EPS beats suggest demand resilience, though the article’s forward growth deceleration is a caution signal.
Primarily US healthcare/dental equipment sentiment; limited direct regional spillover described.
No explicit global macro or international regulatory drivers mentioned beyond company performance.
Counterpoint
The forward revenue growth outlook (1.1% over 12 months) suggests the beat may not translate into sustained top-line momentum.
Key entities
- companyEnvista Holdings
Reported Q2 CY2026 revenue and adjusted EPS results, with raised FY EPS guidance and a noted deceleration in expected revenue growth.
- executivePaul Keel
CEO quoted saying the company built on a strong Q1 into Q2.